Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

Fred Hutchinson Cancer Center (FHCC)

Status: Completed

Conditions: Multiple Myeloma; Hodgkin Disease; Myelodysplastic Syndrome; Leukemia; Non-Hodgkin Lymphoma

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT01141959

IR-7093 (Other Identifier)

R01HL091744-02S1 (U.S. NIH Grant/Contract)

FHCRC-2373.00

Details and patient eligibility

About

The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Scheduled to receive nonmyeloablative conditioning which includes fludarabine
• Scheduled to receive a haploidentical graft
• Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid
• Age >18 years at the time of enrollment

Exclusion criteria

• Diagnosed with an immunodeficiency disorder, including HIV